175 related articles for article (PubMed ID: 19714488)
21. Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig JM; Armel SR; Novokmet A; Ginsburg OM; Demsky R; Narod SA; Malkin D
Fam Cancer; 2012 Dec; 11(4):607-13. PubMed ID: 22851211
[TBL] [Abstract][Full Text] [Related]
22. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
23. [Description of a new TP53 gene germline mutation in a family with the Li-Fraumeni syndrome. Genetic counselling to healthy mutation carriers].
Balmaña J; Nomdedéu J; Díez O; Sabaté JM; Balil A; Pericay C; López López JJ; Brunet J; Baiget M; Alonso C
Med Clin (Barc); 2002 Oct; 119(13):497-9. PubMed ID: 12406399
[TBL] [Abstract][Full Text] [Related]
24. [Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].
Yang X; Hu Z; Wu J; Liu G; Di G; Chen C; Hou Y; Huang X; Liu Z; Shen Z; Shao Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Dec; 32(6):761-5. PubMed ID: 26663043
[TBL] [Abstract][Full Text] [Related]
25. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
26. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
27. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
28. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites.
Rapakko K; Allinen M; Syrjäkoski K; Vahteristo P; Huusko P; Vähäkangas K; Eerola H; Kainu T; Kallioniemi OP; Nevanlinna H; Winqvist R
Br J Cancer; 2001 Jan; 84(1):116-9. PubMed ID: 11139324
[TBL] [Abstract][Full Text] [Related]
29. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
30. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.
Lehman TA; Haffty BG; Carbone CJ; Bishop LR; Gumbs AA; Krishnan S; Shields PG; Modali R; Turner BC
Cancer Res; 2000 Feb; 60(4):1062-9. PubMed ID: 10706125
[TBL] [Abstract][Full Text] [Related]
31. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
32. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.
Gao F; Pan X; Dodd-Eaton EB; Recio CV; Montierth MD; Bojadzieva J; Mai PL; Zelley K; Johnson VE; Braun D; Nichols KE; Garber JE; Savage SA; Strong LC; Wang W
Genome Res; 2020 Aug; 30(8):1170-1180. PubMed ID: 32817165
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
[TBL] [Abstract][Full Text] [Related]
34. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
Masciari S; Dillon DA; Rath M; Robson M; Weitzel JN; Balmana J; Gruber SB; Ford JM; Euhus D; Lebensohn A; Telli M; Pochebit SM; Lypas G; Garber JE
Breast Cancer Res Treat; 2012 Jun; 133(3):1125-30. PubMed ID: 22392042
[TBL] [Abstract][Full Text] [Related]
36. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases.
Fostira F; Konstantopoulou I; Mavroudis D; Tryfonopoulos D; Yannoukakos D; Voutsinas GE
Clin Genet; 2015 Apr; 87(4):383-7. PubMed ID: 24702488
[TBL] [Abstract][Full Text] [Related]
37. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.
Evans DG; Woodward ER
Fam Cancer; 2021 Jan; 20(1):1-7. PubMed ID: 32984917
[No Abstract] [Full Text] [Related]
38. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
[TBL] [Abstract][Full Text] [Related]
39. TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.
Pinto C; Veiga I; Pinheiro M; Peixoto A; Pinto A; Lopes JM; Reis RM; Oliveira C; Baptista M; Roque L; Regateiro F; Cirnes L; Hofstra RM; Seruca R; Castedo S; Teixeira MR
Fam Cancer; 2009; 8(4):383-90. PubMed ID: 19468865
[TBL] [Abstract][Full Text] [Related]
40. Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.
Bakhuizen JJ; Velthuizen ME; Stehouwer S; Bleiker EM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):231-239. PubMed ID: 30238178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]